Topical tacrolimus and pimecrolimus are not associated with skin atrophy.
Bos
J D
JD
D001284:Atrophy / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D012867:Skin / Q000473:pathology*; D016559:Tacrolimus / Q000009:adverse effects* / Q000031:analogs & derivatives
D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus